This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lesic, B. Articles by Carniel, E. Search for Related Content PubMed PubMed Citation Articles by Lesic, B. Articles by Carniel, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2002, p. 1741-1745, Vol. 46, No. 6
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.6.1741-1745.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Comparison of the Effects of Deferiprone versus Deferoxamine on Growth and Virulence of Yersinia enterocolitica

Biliana Lesic, Jeannine Foulon, and Elisabeth Carniel^*

Laboratoire des Yersinia, Institut Pasteur, 75724 Paris Cedex 15, France

Received 8 October 2001/ Returned for modification 11 December 2001/ Accepted 8 February 2002

Deferoxamine, a drug used to treat patients with iron overload, has the capacity to promote systemic Y. enterocolitica infections in humans. The aim of this study was to determine whether deferiprone, the only orally active alternative treatment, has the same potential. When Y. enterocolitica IP864 was grown in an iron-poor chemically defined medium, addition of deferoxamine promoted its growth, while various concentrations of deferiprone did not display this activity. Similarly, on iron-poor agar plates, various Y. enterocolitica strains were able to grow around paper disks impregnated with deferoxamine in a dose-dependent manner, while no growth was observed around the deferiprone disks. In a mouse experimental model of infection, the 50% lethal dose (LD₅₀) of strain IP864 was decreased by more than 5 log units in mice pretreated with deferoxamine, while a deferiprone pretreatment did not affect it. Therefore, in contrast to deferoxamine, deferiprone does not enhance growth of pathogenic Y. enterocolitica in vitro and does not have the potential to promote Y. enterocolitica septicemia in a mouse model of infection. Deferiprone may thus represent a useful alternative iron-chelation therapy during invasive Y. enterocolitica infections.

---

* Corresponding author. Mailing address: Laboratoire des Yersinia, Institut Pasteur, 28 rue du Dr. Roux, 75724 Paris Cedex 15, France. Phone: (33)-1-45-68-83-26. Fax: (33)-1-40-61-30-01. E-mail: carniel2{at}pasteur.fr.

---

Antimicrobial Agents and Chemotherapy, June 2002, p. 1741-1745, Vol. 46, No. 6
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.6.1741-1745.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Jabado, N., Cuellar-Mata, P., Grinstein, S., Gros, P. (2003). Iron chelators modulate the fusogenic properties of Salmonella-containing phagosomes. Proc. Natl. Acad. Sci. USA 100: 6127-6132 [Abstract] [Full Text]